sábado, 7 junho, 2025
No Result
View All Result
Folha Nobre
  • Todas Notícias
  • Rondônia
  • PodCast
  • Expediente
Folha Nobre
No Result
View All Result
Folha Nobre
No Result
View All Result

Fiocruz denounces diversion of malaria drugs to miners

30/01/2023
in English

Medicines against malaria that should be being used among the Yanomami people are being diverted to miners who work illegally in the indigenous territory. The complaint was made to the Ministry of Health (MS) by the Oswaldo Cruz Foundation (Fiocruz) and confirmed this Monday (30) to the press. “On January 18, the Institute of Pharmaceutical Technology (Farmanguinhos/Fiocruz) sent a letter to the General Coordination of Pharmaceutical Assistance and Strategic Medicines, of the Secretariat of Sciences, Technologies and Strategic Inputs (MS), to notify the body of this of information on the illegal commercialization of a batch of medicine (artesunate + mefloquine) produced by the institute for the treatment of malaria. The drug in question is being sold by prospectors in a location close to the Yanomami indigenous territory,” Fiocruz said in a statement. According to the foundation, the batch was fully delivered to the MS Distribution and Logistics Center, and the notification by means of an official letter occurred as part of the internal protocol, so that the agency is aware and can take the measures it deems appropriate in view of the shared information. The information was obtained by Fiocruz from the complaint. Questioned, the Ministry of Health reported that it will investigate with the competent bodies.

Agência Brasil

Tags: denouncesdiversiondrugsFiocruzmaláriaminers

Podcast

Folha Nobre - Desde 2013 - ©

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • Todas Notícias
  • Rondônia
  • PodCast
  • Expediente

Folha Nobre - Desde 2013 - ©

Este site usa cookies. Ao continuar a usar este site, você concorda com o uso de cookies. Visite a página Política de Privacidade.